Bailard’s Amneal Pharmaceuticals AMRX Stock Holding History

Bailard’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-44,200	Closed	-$141K	–	666
2022 Q2	$141K	Buy	+44,200	New	+$160K	0.01%	639

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bailard's AMRX Position: Q3 2022 in Review

Bailard sold out of Amneal Pharmaceuticals (AMRX) in Q3 2022, closing a stake of 44,200 shares — an estimated $141K sold.

Bailard first reported a position in AMRX in Q2 2022 and held it in 1 quarter. The position peaked at $141K in Q2 2022. 154 funds tracked by Wall St. Rank hold AMRX as of Q3 2022.

Bailard reported no remaining Amneal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Bailard sold 44,200 Amneal Pharmaceuticals shares in Q3 2022, an estimated $141K.
Bailard first reported a position in Amneal Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Bailard's Amneal Pharmaceuticals position peaked at $141K in Q2 2022.
154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.